Considerations for deriving a safe intake of propylene glycol

被引:5
作者
Lewis, Ari S. [1 ]
Boomhower, Steven R. [1 ,2 ]
Marsh, Charlotte M. [1 ]
Jack, Maia M. [3 ]
机构
[1] Gradient, Boston, MA 02108 USA
[2] Harvard Univ, Harvard Div Continuing Educ, Cambridge, MA 02138 USA
[3] Amer Beverage Assoc, Washington, DC 20004 USA
关键词
GAP METABOLIC-ACIDOSIS; INCREASED OSMOLAR GAP; LORAZEPAM INFUSION; SERUM OSMOLALITY; ETHYLENE-GLYCOL; TOXICITY; PHARMACOKINETICS; PATIENT; HYPEROSMOLALITY; ERYTHROCYTES;
D O I
10.1016/j.fct.2024.114460
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The use of propylene glycol (PG) in food and other applications is widespread, and some estimates of dietary exposure to PG approach or exceed the Acceptable Daily Intake (ADI) of 25 mg/kg bw-day. The current ADI for PG applies a cumulative uncertainty factor of 100, which includes factors of 10 for both interspecies and intraspecies differences. Available toxicology studies and human data, however, indicate a plausible mode of action (MoA) that would support a chemical-specific adjustment factor (CSAF) of 1 for interspecies toxicodynamic differences, reducing the total uncertainty factor from 100 to 40. The MoA involves an increase in serum PG concentrations after metabolic saturation, leading to serum hyperosmolarity, which can ultimately cause hemolytic changes and red blood cell damage. Therefore, the species similarities in toxicodynamic response for this critical effect could support increasing the ADI from 25 to 62.5 mg/kg bw-day, applicable to both children and adults.
引用
收藏
页数:14
相关论文
共 81 条
[1]  
Agency for Toxic Substances and Disease Registry (ATSDR), 1997, Toxicological Profile for Propylene Glycol, P176
[2]   Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis [J].
Al-Khafaji, AH ;
Dewhirst, WE ;
Manning, HL .
ANESTHESIA AND ANALGESIA, 2002, 94 (06) :1583-1585
[3]  
Alcorn J, 2002, CLIN PHARMACOKINET, V41, P1077, DOI 10.2165/00003088-200241130-00005
[4]   Prospective assessment of short-term propylene glycol tolerance in neonates [J].
Allegaert, Karel ;
Vanhaesebrouck, Sophie ;
Kulo, Aida ;
Cosaert, Katrien ;
Verbesselt, Rene ;
Debeer, Anne ;
de Hoon, Jan .
ARCHIVES OF DISEASE IN CHILDHOOD, 2010, 95 (12) :1054-1058
[5]   Osmolar gap metabolic acidosis in a 60-year-old man treated for hypoxemic respiratory failure - Propylene glycol toxicity caused by escalating lorazepam infusion. [J].
Arbour, R ;
Esparis, B .
CHEST, 2000, 118 (02) :545-546
[6]  
Arbour R B, 1999, Am J Crit Care, V8, P499
[7]   Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults [J].
Arroliga, AC ;
Shehab, N ;
McCarthy, K ;
Gonzales, JP .
CRITICAL CARE MEDICINE, 2004, 32 (08) :1709-1714
[8]   Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation [J].
Barnes, BJ ;
Gerst, C ;
Smith, JR ;
Terrell, AR ;
Mullins, ME .
PHARMACOTHERAPY, 2006, 26 (01) :23-33
[9]  
Baskurt OK, 2003, SEMIN THROMB HEMOST, V29, P435
[10]  
Bessman J.D., 1990, Clinical Methods: The History, Physical, and Laboratory Examinations, P735